Literature DB >> 31798972

Guideline for the identification and management of cardiometabolic risk after spinal cord injury: a case of unsubstantiated recommendations.

Michael D Stillman1, Steve Williams2.   

Abstract

The 2018 Guideline for the Identification and Management of Cardiometabolic Risk after Spinal Cord Injury (SCI) represented the first concerted effort to address a cluster of derangements and diseases that are claiming the lives of individuals living with injuries. Its contributors and authors scoured the literature, weighed the validity, importance, and clinical relevance of what data they found, and collaborated in an effort to meaningfully improve the health and lives of people with SCI. However, we are concerned that several of the guideline's central recommendations-particularly around screening for and detection of glycemic dysregulation and dyslipidemia-have been offered prematurely. In several instances, the authors cite data from studies of people without SCI and, in our opinion, inappropriately apply those findings to support their SCI-specific suggestions. In other instances, they recommend that we employ tests whose usefulness and clinical relevance have yet to be demonstrated among people living with injuries. In short, we fear that the authors have developed clinical guidelines that are inadequately supported by data. This guideline is an extraordinary show of collaboration, and is an important first step toward understanding and treating a number of secondary cardiometabolic effects of SCI. The lack of data underpinning several of its central recommendations-making them, in our opinion, unadoptable-underscores the inadequacy of research in this area and provides a roadmap for future investigative efforts. © International Spinal Cord Society 2019.

Entities:  

Keywords:  Dyslipidaemias; Spinal cord diseases

Mesh:

Year:  2019        PMID: 31798972      PMCID: PMC6881404          DOI: 10.1038/s41394-019-0240-6

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  29 in total

1.  Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial.

Authors:  Mark S Nash; John E Lewis; Trevor A Dyson-Hudson; Yaga Szlachcic; Florence Yee; Armando J Mendez; Ann M Spungen; William A Bauman
Journal:  Arch Phys Med Rehabil       Date:  2011-01-31       Impact factor: 3.966

2.  Evaluating the prevalence of silent coronary artery disease in asymptomatic patients with spinal cord injury.

Authors:  Chee-Siong Lee; Ye-Hsu Lu; Shuo-Tsan Lee; Ching-Cheng Lin; Hueisch-Jy Ding
Journal:  Int Heart J       Date:  2006-05       Impact factor: 1.862

3.  Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis.

Authors:  Joseph Yeboah; Aaron R Folsom; Gregory L Burke; Craig Johnson; Joseph F Polak; Wendy Post; Joao A Lima; John R Crouse; David M Herrington
Journal:  Circulation       Date:  2009-07-27       Impact factor: 29.690

4.  American Diabetes Association Standards of Medical Care in Diabetes 2017.

Authors:  Payal H Marathe; Helen X Gao; Kelly L Close
Journal:  J Diabetes       Date:  2017-04       Impact factor: 4.006

5.  Cardiac stress testing with thallium-201 imaging reveals silent ischemia in individuals with paraplegia.

Authors:  W A Bauman; M Raza; A M Spungen; J Machac
Journal:  Arch Phys Med Rehabil       Date:  1994-09       Impact factor: 3.966

6.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Authors:  Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn
Journal:  N Engl J Med       Date:  2008-11-09       Impact factor: 91.245

7.  Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging.

Authors:  W A Bauman; A M Spungen
Journal:  Metabolism       Date:  1994-06       Impact factor: 8.694

8.  Elevated C-reactive protein associated with decreased high-density lipoprotein cholesterol in men with spinal cord injury.

Authors:  Huifang Liang; Mina C Mojtahedi; David Chen; Carol L Braunschweig
Journal:  Arch Phys Med Rehabil       Date:  2008-01       Impact factor: 3.966

9.  Association between mobility mode and C-reactive protein levels in men with chronic spinal cord injury.

Authors:  Leslie R Morse; Kelly Stolzmann; Hiep P Nguyen; Nitin B Jain; Cara Zayac; David R Gagnon; Carlos G Tun; Eric Garshick
Journal:  Arch Phys Med Rehabil       Date:  2008-04       Impact factor: 3.966

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  4 in total

Review 1.  Point: Counterpoint synopsis of cardiometabolic risk after spinal cord injury.

Authors:  David R Gater
Journal:  Spinal Cord Ser Cases       Date:  2019-11-27

Review 2.  Neurogenic Obesity-Induced Insulin Resistance and Type 2 Diabetes Mellitus in Chronic Spinal Cord Injury.

Authors:  Phillip S Gordon; Gary J Farkas; David R Gater
Journal:  Top Spinal Cord Inj Rehabil       Date:  2021

3.  Body composition and bone mineral density in athletes with a physical impairment.

Authors:  Valentina Cavedon; Marco Sandri; Ilaria Peluso; Carlo Zancanaro; Chiara Milanese
Journal:  PeerJ       Date:  2021-05-10       Impact factor: 2.984

4.  Comparison of Various Indices in Identifying Insulin Resistance and Diabetes in Chronic Spinal Cord Injury.

Authors:  Gary J Farkas; Phillip S Gordon; Nareka Trewick; Ashraf S Gorgey; David R Dolbow; Eduard Tiozzo; Arthur S Berg; David R Gater
Journal:  J Clin Med       Date:  2021-11-28       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.